Joseph Lewis Izzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph Lewis Izzo has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Peter J. Osmond
Department of Medicine, Jacobs School of Medicine, University at Buffalo, Buffalo, New York
8 shared publicationsDas Purkayastha
Novartis Pharmaceuticals Corporation
4 shared publications- Sheldon William Tobe
Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Canada; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada; Northern Ontario School of Medicine, Sudbury, Canada
4 shared publications Benjamin Gavish
Yazmonit LTD, Jerusalem, ISRAEL
3 shared publications- Howard Weintraub
New York University School of Medicine, New York, NY
3 shared publications Peter Osmond
Department of Medicine, Jacobs School of Medicine, State University of New York at Buffalo, New York, USA
3 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (10) , 1222-1230
Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate
Background: There is little information about systemic hemodynamic changes in the evolution of heart failure (HF) from hypertension. Methods: We compared 24-hr mean hemodynamic variables derived from ambulatory pulse wave analysis (Mobil-O-Graph) in at-risk patients with hypertension (Stage A/B HF) and patients with Stage C HF secondarily stratified by ejection fraction (EF: low <40% or high ≥40%). Results: Differences (mean ± SEM) between Stage A/B (n = 109) and Stage C HF (n = 52) were, respectively: stroke volume index (SVI) 36.8 vs. 31.9 mL/m2 (P<.001), heart rate (HR) 68.1 vs. 76.4 bpm (P<.001), and arterial stiffness (pulse pressure/SVI) 1.47 vs. 1.65 mmHg/mL/m2 (P<.05); cardiac index and total vascular resistance index did not differ between groups. Robust inverse correlations between SVI and HR were found in both Stage A/B and Stage C HF (P < .001); each 10 beat/min change in HR was accompanied by a reciprocal SVI change of 3 mL/m2; overall, SVI was 5-10% lower in Stage C compared to Stage A/B HF. Hemodynamic profiles, especially high HR and low SVI, were quantitatively similar in Stage C HF patients with low or high EF. Low SVI (75 bpm) increased specificity to 84%. Conclusions: Ambulatory hemodynamic monitoring is feasible in HF patients; low 24-hour SVI and high HR are highly correlated and together can differentiate Stage C from Stage A/B HF, irrespective of EF. Further study of hemodynamic profiles in HF staging and prognosis is warranted.
- 3 July 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (10) , 1222-1230
Open AccessHemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate
Background: There is little information about systemic hemodynamic changes in the evolution of heart failure (HF) from hypertension. Methods: We compared 24-hr mean hemodynamic variables derived from ambulatory pulse wave analysis (Mobil-O-Graph) in at-risk patients with hypertension (Stage A/B HF) and patients with Stage C HF secondarily stratified by ejection fraction (EF: low <40% or high ≥40%). Results: Differences (mean ± SEM) between Stage A/B (n = 109) and Stage C HF (n = 52) were, respectively: stroke volume index (SVI) 36.8 vs. 31.9 mL/m2 (P<.001), heart rate (HR) 68.1 vs. 76.4 bpm (P<.001), and arterial stiffness (pulse pressure/SVI) 1.47 vs. 1.65 mmHg/mL/m2 (P<.05); cardiac index and total vascular resistance index did not differ between groups. Robust inverse correlations between SVI and HR were found in both Stage A/B and Stage C HF (P < .001); each 10 beat/min change in HR was accompanied by a reciprocal SVI change of 3 mL/m2; overall, SVI was 5-10% lower in Stage C compared to Stage A/B HF. Hemodynamic profiles, especially high HR and low SVI, were quantitatively similar in Stage C HF patients with low or high EF. Low SVI (75 bpm) increased specificity to 84%. Conclusions: Ambulatory hemodynamic monitoring is feasible in HF patients; low 24-hour SVI and high HR are highly correlated and together can differentiate Stage C from Stage A/B HF, irrespective of EF. Further study of hemodynamic profiles in HF staging and prognosis is warranted.
- Top Cited Papers
- 18 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (20) , 1411-1422
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed. RESULTS: Of 2401 patients (median age, 69 [Q1–Q3, 58–77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68–1.08]; P =0.20). A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71–1.18]). Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48–1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43–1.00]). The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively. In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54–0.93] P =0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41–0.80]; P =0.001). CONCLUSIONS: In this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04363697.
- 18 November 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (20) , 1411-1422
Top Cited PapersDapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed. RESULTS: Of 2401 patients (median age, 69 [Q1–Q3, 58–77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68–1.08]; P =0.20). A worsening HF event occurred in 115 (9.4%) and 122 (10.3%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.91 [95% CI, 0.71–1.18]). Cardiovascular death occurred in 30 (2.5%) and 37 (3.1%) patients (HR, 0.78 [95% CI, 0.48–1.27]), and death from any cause occurred in 36 (3.0%) and 53 (4.5%) patients in the dapagliflozin and placebo groups, respectively (HR, 0.66 [95% CI, 0.43–1.00]). The rates of symptomatic hypotension were 3.6% and 2.2%, and the rates of worsening kidney function were 5.9% and 4.7% with dapagliflozin and placebo, respectively. In a meta-analysis of patients hospitalized for HF, SGLT2 inhibitors reduced the early risk of cardiovascular death or worsening HF (HR, 0.71 [95% CI, 0.54–0.93] P =0.012) and of all-cause death (HR, 0.57 [95% CI, 0.41–0.80]; P =0.001). CONCLUSIONS: In this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04363697.
- 9 December 2022
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 37 (10) , 891-897
Impact of arterial location, pressure wave indicators, and measurement devices on arterial form factor and mean and central arterial pressure
Mean arterial pressure (MAP) is often estimated from cuff systolic (S) and diastolic (D) blood pressure (BP) using a fixed arterial form factor (FF, usually 0.33). If MAP is measured directly, a true FF can be calculated: FF = [MAP–DBP]/[SBP–DBP]. Because waveform shapes vary, true FF should also vary and MAP accuracy will be affected. We studied factors affecting FF using radial tonography (SphygmoCor, n = 376) or brachial oscillometry (Mobil-O-Graph, n = 157) and to compare devices, 101 pairs were matched precisely for SBP and DBP. SphygmoCor brachioradial FF correlated strongly with central FF (r2 = 0.75), central augmentation index (cAI, r2 = 0.39), and inversely with pulse pressure amplification (PPA) ratio (r2 = 0.44) [all p < 0.000]; brachioradial FF was lower than central (c) FF (0.34 vs. 0.44, 95% CI’s [0.23,0.46] and [0.34,0.54], p < 0.000). On forward stepwise regression, brachioradial FF correlated with PPA ratio, age, heart rate, and cAI (multiple-r2 0.63, p < 0.000). With Mobil-O-Graph: brachial FF was fixed, lower than the corresponding cFF [mean(SD)] 0.46(0.00098) vs. 0.57(0.048), p < 0.000], and uncorrelated with clinical characteristics; MAP and cSBP were higher than SphygmoCor by 6.3 and 2.2 mmHg (p < 0.005) at the midpoint with systematic negative biases. We conclude that FF derived from radial tonometry (SphygmoCor) varies with pulse wave morphology within and between individuals and by measurement site, age, and heart rate. With oscillometry (Mobil-O-Graph), brachial FF was fixed and high and unrelated to other clinical variables; MAP and cSBP were higher than tonometry, with systematic negative biases.
- 9 December 2022
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 37 (10) , 891-897
Impact of arterial location, pressure wave indicators, and measurement devices on arterial form factor and mean and central arterial pressure
Mean arterial pressure (MAP) is often estimated from cuff systolic (S) and diastolic (D) blood pressure (BP) using a fixed arterial form factor (FF, usually 0.33). If MAP is measured directly, a true FF can be calculated: FF = [MAP–DBP]/[SBP–DBP]. Because waveform shapes vary, true FF should also vary and MAP accuracy will be affected. We studied factors affecting FF using radial tonography (SphygmoCor, n = 376) or brachial oscillometry (Mobil-O-Graph, n = 157) and to compare devices, 101 pairs were matched precisely for SBP and DBP. SphygmoCor brachioradial FF correlated strongly with central FF (r2 = 0.75), central augmentation index (cAI, r2 = 0.39), and inversely with pulse pressure amplification (PPA) ratio (r2 = 0.44) [all p < 0.000]; brachioradial FF was lower than central (c) FF (0.34 vs. 0.44, 95% CI’s [0.23,0.46] and [0.34,0.54], p < 0.000). On forward stepwise regression, brachioradial FF correlated with PPA ratio, age, heart rate, and cAI (multiple-r2 0.63, p < 0.000). With Mobil-O-Graph: brachial FF was fixed, lower than the corresponding cFF [mean(SD)] 0.46(0.00098) vs. 0.57(0.048), p < 0.000], and uncorrelated with clinical characteristics; MAP and cSBP were higher than SphygmoCor by 6.3 and 2.2 mmHg (p < 0.005) at the midpoint with systematic negative biases. We conclude that FF derived from radial tonometry (SphygmoCor) varies with pulse wave morphology within and between individuals and by measurement site, age, and heart rate. With oscillometry (Mobil-O-Graph), brachial FF was fixed and high and unrelated to other clinical variables; MAP and cSBP were higher than tonometry, with systematic negative biases.
- Open Access
- 2 August 2022
- Published by Springer Nature in Research Square
Impact of Arterial Location, Pressure Wave Indicators, and Measurement Devices on Arterial Form Factor and Mean and Central Arterial Pressure
Mean arterial pressure (MAP) is often estimated from cuff systolic (S) and diastolic (D) blood pressure (BP) using a fixed arterial form factor (FF, usually 0.33). If MAP is measured accurately, a true FF can be calculated: FF = [MAP–DBP] / [SBP–DBP]. Because waveform shapes vary, true measured FF should also vary and MAP accuracy may be affected. We studied factors affecting FF using radial tonography (SphygmoCor, n = 376) or brachial oscillometry (Mobil-O-Graph, n = 157) and to compare devices, 101 pairs were matched precisely for SBP and DBP. SphygmoCor brachioradial FF correlated strongly with central FF (r2 = 0.75), central augmentation index (cAI, r2 = 0.39), and inversely with pulse pressure amplification (PPA) ratio (r2 = 0.44) [all p < 0.000]; brachioradial FF was lower than central (c) FF (0.34 vs 0.44, 95% CI’s [0.23,0.46] and [0.34,0.54], p < 0.000); and on forward stepwise regression, brachioradial FF correlated with PPA ratio, age, heart rate, and cAI (multiple-r2 0.63, p < 0.000). With Mobil-O-Graph: brachial FF was fixed, lower than the corresponding cFF [mean(SD)] 0.46(0.00098) vs 0.57(0.048), p < 0.000], and uncorrelated with other characteristics; MAP and cSBP were higher than SphygmoCor by 6.3 and 2.2 mmHg (p < 0.005) but also had significant systematic negative biases. We conclude that with radial tonometry (SphygmoCor), FF varies with pulse wave morphology within and between individuals and by measurement site, age, and heart rate. With oscillometry (Mobil-O-Graph), brachial FF was unrelated to other clinical variables, fixed and high; MAP and cSBP were higher than tonometry, with systematic negative biases.
- 2 August 2022
- Published by Springer Nature in Research Square
Open AccessImpact of Arterial Location, Pressure Wave Indicators, and Measurement Devices on Arterial Form Factor and Mean and Central Arterial Pressure
Mean arterial pressure (MAP) is often estimated from cuff systolic (S) and diastolic (D) blood pressure (BP) using a fixed arterial form factor (FF, usually 0.33). If MAP is measured accurately, a true FF can be calculated: FF = [MAP–DBP] / [SBP–DBP]. Because waveform shapes vary, true measured FF should also vary and MAP accuracy may be affected. We studied factors affecting FF using radial tonography (SphygmoCor, n = 376) or brachial oscillometry (Mobil-O-Graph, n = 157) and to compare devices, 101 pairs were matched precisely for SBP and DBP. SphygmoCor brachioradial FF correlated strongly with central FF (r2 = 0.75), central augmentation index (cAI, r2 = 0.39), and inversely with pulse pressure amplification (PPA) ratio (r2 = 0.44) [all p < 0.000]; brachioradial FF was lower than central (c) FF (0.34 vs 0.44, 95% CI’s [0.23,0.46] and [0.34,0.54], p < 0.000); and on forward stepwise regression, brachioradial FF correlated with PPA ratio, age, heart rate, and cAI (multiple-r2 0.63, p < 0.000). With Mobil-O-Graph: brachial FF was fixed, lower than the corresponding cFF [mean(SD)] 0.46(0.00098) vs 0.57(0.048), p < 0.000], and uncorrelated with other characteristics; MAP and cSBP were higher than SphygmoCor by 6.3 and 2.2 mmHg (p < 0.005) but also had significant systematic negative biases. We conclude that with radial tonometry (SphygmoCor), FF varies with pulse wave morphology within and between individuals and by measurement site, age, and heart rate. With oscillometry (Mobil-O-Graph), brachial FF was unrelated to other clinical variables, fixed and high; MAP and cSBP were higher than tonometry, with systematic negative biases.
- 1 August 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (2) , 372-375
Pitfalls of Pulse Wave Analysis and Oscillometric Blood Pressure Derivatives
- 1 August 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (2) , 372-375
Pitfalls of Pulse Wave Analysis and Oscillometric Blood Pressure Derivatives
- Open Access
- 24 December 2019
- Published by Springer Nature in Artery Research
- Vol. 25 (3-4) , 165-169
Dissociation of Carotid and Forearm Pressure Decay Constants (tau), Windkessel Compliances, and Pulse Wave Velocities: Implications for Circulatory Models
- 24 December 2019
- Published by Springer Nature in Artery Research
- Vol. 25 (3-4) , 165-169
Open AccessDissociation of Carotid and Forearm Pressure Decay Constants (tau), Windkessel Compliances, and Pulse Wave Velocities: Implications for Circulatory Models
- Open Access
- 24 December 2019
- Published by Springer Nature in Artery Research
- Vol. 25 (3-4) , 87-94
Decoupling of Heart Rate and Blood Pressure: Hemodynamic Counter-regulatory Mechanisms and their Implications
To investigate the dynamic relationships among Heart Rate (HR) and systemic hemodynamics in everyday life, we performed 24-h ambulatory pulse wave analyses (Mobil-O-Graph) in individuals with normal and elevated BP (n = 116) and in a double-blinded cross-over study where HR was varied pharmacologically (n = 24). In the whole cohort and in the low [24-h mean Systolic BP (SBP) < 135 mmHg] and high (SBP ≥ 135 mmHg) groups, mean HR did not correlate with mean SBP but did correlate strongly and negatively with Stroke Volume Index (SVI) and Systemic Vascular Resistance Index (SVRI) over 24 h and during night-time and daytime periods (all p < 0.000). SVI varied by about 0.2 mL/m2 per bpm in both BP groups, while SVRI varied by about 0.03 and 0.01 mmHg.s.m2/mL per bpm in the high and low BP groups, respectively, p < 0.001). On stepwise multiple linear regression, there was greater sensitivity of SVI to HR in Blacks and younger individuals, and greater sensitivity of SVRI to HR with age in addition to higher SBP. In a crossover study (monotherapy for 1 month each with nebivolol or valsartan), BP was constant throughout, while SVI and SVRI varied inversely with HR as in the main cohort with similar intercepts and coefficients; the regression equations on either drug predicted the same SVI or SVRI at HR of 70 bpm. We conclude that the decoupling of BP from HR is facilitated by the continuous counter-regulation of SVI and SVRI against HR and that HR is the primary hemodynamic setpoint. These findings have implications for pathogenetic studies and imply that hemodynamic measurements should be corrected for HR.
- 24 December 2019
- Published by Springer Nature in Artery Research
- Vol. 25 (3-4) , 87-94
Open AccessDecoupling of Heart Rate and Blood Pressure: Hemodynamic Counter-regulatory Mechanisms and their Implications
To investigate the dynamic relationships among Heart Rate (HR) and systemic hemodynamics in everyday life, we performed 24-h ambulatory pulse wave analyses (Mobil-O-Graph) in individuals with normal and elevated BP (n = 116) and in a double-blinded cross-over study where HR was varied pharmacologically (n = 24). In the whole cohort and in the low [24-h mean Systolic BP (SBP) < 135 mmHg] and high (SBP ≥ 135 mmHg) groups, mean HR did not correlate with mean SBP but did correlate strongly and negatively with Stroke Volume Index (SVI) and Systemic Vascular Resistance Index (SVRI) over 24 h and during night-time and daytime periods (all p < 0.000). SVI varied by about 0.2 mL/m2 per bpm in both BP groups, while SVRI varied by about 0.03 and 0.01 mmHg.s.m2/mL per bpm in the high and low BP groups, respectively, p < 0.001). On stepwise multiple linear regression, there was greater sensitivity of SVI to HR in Blacks and younger individuals, and greater sensitivity of SVRI to HR with age in addition to higher SBP. In a crossover study (monotherapy for 1 month each with nebivolol or valsartan), BP was constant throughout, while SVI and SVRI varied inversely with HR as in the main cohort with similar intercepts and coefficients; the regression equations on either drug predicted the same SVI or SVRI at HR of 70 bpm. We conclude that the decoupling of BP from HR is facilitated by the continuous counter-regulation of SVI and SVRI against HR and that HR is the primary hemodynamic setpoint. These findings have implications for pathogenetic studies and imply that hemodynamic measurements should be corrected for HR.
- 26 July 2019
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (8) , 1183-1190
Maintenance of long‐term blood pressure control and vascular health by low‐dose amiloride‐based therapy in hyperaldosteronism
Whether aldosterone itself contributes directly to macro‐ or microcirculatory disease in man or to adverse cardiovascular outcomes is not fully known. We report our long‐term single‐practice experience in an unusual group of five patients with chronic hyperaldosteronism (HA, including three with glucocorticoid‐remediable aldosteronism, GRA) treated with low‐dose amiloride (a specific epithelial sodium channel [ENaC] blocker) 5‐10 (mean 7) mg daily for 14‐28 (mean 20) years. Except for one GRA diagnosed in infancy, all had severe resistant hypertension. In each case, BP was normalized within 1‐4 weeks after starting amiloride and office BP’s remained well controlled throughout the next two decades. 24‐hour ambulatory BP monitoring with pulse wave analysis (cardiac output, vascular resistance, augmentation index, reflection magnitude), regional pulse wave velocities, pulse stiffening ratio, ankle‐brachial index, serum creatinine, estimated glomerular filtration rate, and spot urinary albumin:creatinine ratio were measured after a mean of 18 years; all of these indicators were essentially normal. Over two additional years of observation (100 patient‐years total), no cardiovascular or renal event occurred. We conclude that long‐term ENaC blockade with amiloride can normalize BP and protect macro‐ and microvascular function in patients with HA. This suggests that either (a) putative vasculopathic effects of aldosterone are mediated via ENaC or (b) aldosterone may not play a direct role in age‐dependent vasculopathic changes in humans independent of blood pressure. These findings, coupled with our literature review in both animal and human results, underscore the need for additional studies.
- 26 July 2019
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (8) , 1183-1190
Maintenance of long‐term blood pressure control and vascular health by low‐dose amiloride‐based therapy in hyperaldosteronism
Whether aldosterone itself contributes directly to macro‐ or microcirculatory disease in man or to adverse cardiovascular outcomes is not fully known. We report our long‐term single‐practice experience in an unusual group of five patients with chronic hyperaldosteronism (HA, including three with glucocorticoid‐remediable aldosteronism, GRA) treated with low‐dose amiloride (a specific epithelial sodium channel [ENaC] blocker) 5‐10 (mean 7) mg daily for 14‐28 (mean 20) years. Except for one GRA diagnosed in infancy, all had severe resistant hypertension. In each case, BP was normalized within 1‐4 weeks after starting amiloride and office BP’s remained well controlled throughout the next two decades. 24‐hour ambulatory BP monitoring with pulse wave analysis (cardiac output, vascular resistance, augmentation index, reflection magnitude), regional pulse wave velocities, pulse stiffening ratio, ankle‐brachial index, serum creatinine, estimated glomerular filtration rate, and spot urinary albumin:creatinine ratio were measured after a mean of 18 years; all of these indicators were essentially normal. Over two additional years of observation (100 patient‐years total), no cardiovascular or renal event occurred. We conclude that long‐term ENaC blockade with amiloride can normalize BP and protect macro‐ and microvascular function in patients with HA. This suggests that either (a) putative vasculopathic effects of aldosterone are mediated via ENaC or (b) aldosterone may not play a direct role in age‐dependent vasculopathic changes in humans independent of blood pressure. These findings, coupled with our literature review in both animal and human results, underscore the need for additional studies.
- Open Access
- 6 June 2019
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (7) , 922-928
Long‐term BP control and vascular health in patients with hyperaldosteronism treated with low‐dose, amiloride‐based therapy
Whether aldosterone itself contributes directly to macro‐ or microcirculatory disease in man or to adverse cardiovascular outcomes is not fully known. We report our long‐term single‐practice experience in 5 patients with chronic hyperaldosteronism (HA, including 3 with glucocorticoid remediable aldosteronism, GRA) treated with low‐dose amiloride (a specific epithelial sodium channel [ENaC] blocker) 5‐10 (mean 7) mg daily for 14‐28 (mean 20) years. Except for 1 GRA diagnosed in infancy, all had severe resistant hypertension. In each case, BP was normal or near‐normal within 1‐4 weeks after starting amiloride and office BP’s were well controlled for 20 years thereafter. Vascular studies and 24‐hour ambulatory BP monitoring with pulse wave analysis (cardiac output, vascular resistance, augmentation index, and reflection magnitude) were assessed after a mean of 18 years as were regional pulse wave velocities, pulse stiffening ratio, ankle‐brachial index, serum creatinine, estimated glomerular filtration rate, and spot urinary albumin:creatinine ratio. All indicators were completely normal in all patients after 18 years of amiloride, and none had a cardiovascular event during the 20‐year mean follow‐up. We conclude that long‐term ENaC blockade can normalize BP and protect macro‐ and microvascular function in patients with HA. This suggests that (a) any vasculopathic effects of aldosterone are mediated via ENaC, not MR activation itself, and are fully preventable or reversible with ENaC blockade or (b) aldosterone may not play a major BP‐independent role in human macro‐ and microcirculatory diseases. These and other widely divergent results in the literature underscore the need for additional studies regarding aldosterone, ENaC, and vascular disease.
- 6 June 2019
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 21 (7) , 922-928
Open AccessLong‐term BP control and vascular health in patients with hyperaldosteronism treated with low‐dose, amiloride‐based therapy
Whether aldosterone itself contributes directly to macro‐ or microcirculatory disease in man or to adverse cardiovascular outcomes is not fully known. We report our long‐term single‐practice experience in 5 patients with chronic hyperaldosteronism (HA, including 3 with glucocorticoid remediable aldosteronism, GRA) treated with low‐dose amiloride (a specific epithelial sodium channel [ENaC] blocker) 5‐10 (mean 7) mg daily for 14‐28 (mean 20) years. Except for 1 GRA diagnosed in infancy, all had severe resistant hypertension. In each case, BP was normal or near‐normal within 1‐4 weeks after starting amiloride and office BP’s were well controlled for 20 years thereafter. Vascular studies and 24‐hour ambulatory BP monitoring with pulse wave analysis (cardiac output, vascular resistance, augmentation index, and reflection magnitude) were assessed after a mean of 18 years as were regional pulse wave velocities, pulse stiffening ratio, ankle‐brachial index, serum creatinine, estimated glomerular filtration rate, and spot urinary albumin:creatinine ratio. All indicators were completely normal in all patients after 18 years of amiloride, and none had a cardiovascular event during the 20‐year mean follow‐up. We conclude that long‐term ENaC blockade can normalize BP and protect macro‐ and microvascular function in patients with HA. This suggests that (a) any vasculopathic effects of aldosterone are mediated via ENaC, not MR activation itself, and are fully preventable or reversible with ENaC blockade or (b) aldosterone may not play a major BP‐independent role in human macro‐ and microcirculatory diseases. These and other widely divergent results in the literature underscore the need for additional studies regarding aldosterone, ENaC, and vascular disease.